Chemical constituents with anti-allergic activity from the root of Edulis Superba, a horticultural cultivar of Paeonia lactiflora
- J Nat Med. 2016 Apr;70(2):234-40. doi: 10.1007/s11418-016-0966-4.
- 1. Division of Pharmacognosy, Department of Medicinal Resources, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
- 2. Division of Pharmacognosy, Department of Medicinal Resources, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. [email protected].
- 3. Toyama Prefectural Medicinal Plants Center, Toyama, 930-0412, Japan.
- 4. Division of Gastrointestinal Pathophysiology, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, 930-0194, Japan.
- 5. The MOE Key Laboratory of Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- 6. Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, 305-0843, Japan.
- 7. Division of Pharmacognosy, Department of Medicinal Resources, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. [email protected].
The methanolic extract and its subfractions from the dried root of Edulis Superba, a horticultural cultivar of Paeonia lactiflora Pallas, showed potent anti-allergic effect as inhibition of immunoglobulin E (IgE)-mediated degranulation in rat basophil leukemia (RBL)-2H3 cells. Bioassay-guided fractionation led to the isolation of 26 compounds, including a new norneolignan glycoside, paeonibenzofuran (1), together with 25 known ones (2-26). The chemical structure of the new compound was elucidated on the basis of spectroscopic and chemical evidences. Among the isolated compounds, mudanpioside E (5) with paeoniflorin-type skeleton and quercetin (16) showed potent inhibitory activity against a degranulation marker, β-hexosaminidase release with IC50 values of 40.34 and 25.05 μM, respectively. A primary structure-activity relationship of these components was discussed.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: OthersResearch Areas: Inflammation/Immunology
-
target: GlycosidaseResearch Areas: Inflammation/Immunology